MetaCap

Obsidian Therapeutics (OBX) vs Syndax Pharmaceuticals (SNDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $741.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OBX-31.43%SNDX-57.50%
+108%+21%-66%
Jul 27, 20261 yearNov 20, 2026
OBX-23.18%SNDX-54.23%
+83%+11%-61%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OBX versus SNDX key metrics
MetricOBXSNDX
Share price$12.00$8.72
Market cap$741.29M$785.05M
1-day change-1.23%-4.49%
YTD return—-58.50%
1-year return—-50.00%
5-year return—-47.09%
EPS (TTM)$-6.52$-2.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$172.35M
Revenue growth (YoY)—+627.84%
Net income (latest FY)—$-285.42M
Operating margin—-158.45%
Net margin—-165.60%
52-week high$49.97$25.59
52-week low$9.60$8.41
Distance from 52-week high-75.99%-65.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+222.25%+306.54%
Average volume511.50K2.63M
Shares outstanding61.77M90.03M
Employees87298
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Obsidian Therapeutics

OBX stock →

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Syndax Pharmaceuticals

SNDX stock →

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees

OBX vs SNDX FAQ

Which is bigger, Obsidian Therapeutics or Syndax Pharmaceuticals?

Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $741.29M for Obsidian Therapeutics (OBX).

Are Obsidian Therapeutics and Syndax Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons